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Abstract
A methodology based on the representation of each amino acid of a protein sequence by the 
electron-ion interaction potential and subsequent analysis by signal processing was used to 
determine the characteristic or common frequency (in Hz) that reflects the biological activity shared 
among phosphocholine (PC)-binding antibodies. The common frequency for the variable portion of 
the heavy chain (VH) of the PC-specific antibodies is found to be at f = 0.37 Hz. The VH sequences 
of the PC-binding antibodies exhibit three subsites for the PC moiety where hypervariable region 
2 (CDR2) plays a role in the interaction with the phosphate group. Mutations in this VH region have 
an impact on the ability of mutant variants to bind PC and its carrier molecule, as well as on the 
characteristic frequency shift toward f = 0.12 Hz for mutants failing to bind both hapten and carrier. 
The VH sequence of mutants that retain the ability to bind PC still shows f = 0.37 Hz, suggesting that 
this frequency determines PC binding. However, this statement was not confirmed as mutation in 
another PC subsite impairs PC binding but retains both the phosphate-group recognition and the 
frequency at f = 0.37 Hz. Herein, this finding is discussed to promote the idea that the VH sequence 
of the PC-binding antibodies encodes the subsite for phosphate-group binding as a dominant 
functional activity and that only CDR2 of the T15-idiotype antibodies together with FR3 region form 
an autonomous self-association function represented by the T15VH50–73 peptide with f = 0.37 ± 0.05 
Hz. Thus, these data confirmed that T15VH50-73 peptide might be used in superantibody technology.
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Introduction
The sequence diversity of antibodies results from the 
combinatorial re-arrangement of multiple germline variable 
(V), diversity (D) and joining (J) genes but additional diversity 
is generated through junction diversity, as well as subsequent 
somatic mutation of the already re-arranged genes (1). The 
somatic diversification of expressed V region genes that 
occurs during the immune response to phosphocholine (PC) 
is a biologically important problem because of the frequent 
expression of this haptenic epitope on complex antigens such 
as the cell wall and some capsular polysaccharides (PS) of 
pathogenic bacteria, as well as on apoptotic cell membranes 
and oxidized low-density lipoproteins (2, 3). Thus, the need for 
maintenance of genes for antibodies against PC in the germline 
or relatively unchanged configuration in different mice strains is 
logical. In agreement with this belief is the finding that immune 
response in mice to the PC moiety is highly restricted as an 
equivalent set of antibodies to PC in genetically dissimilar mice 
is maintained, implying that genes encoding these antibodies 
are likewise quite similar or in some cases identical (4). The 
anti-PC antibodies raised to PC antigens comprise three main 
families that were initially based on differential recognition by 
anti-idiotypic (anti-Id) antibodies. One family shares public Id 
determinants found on a group of nearly identical PC-binding 
myeloma proteins (MP) S107/TEPC-15 (also termed the T15 
idiotype family) and two others on anti-PC MP, MOPC-167/511 
(also termed M511) and McPC-603 (also termed M603) (5, 6). 
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High doses of Id antibodies directed against anti-PC antibodies 
have been shown to lead to clonal deletion of T15-bearing B 
cells (7). These idiotype families are very closely related and 
their heavy-chain variable region (VH) domains are transcribed 
from the same VH gene segment (6, 7). However, each of the 
three families uses a distinct V region for its light (L) chains 
encoded by three different VL genes, VK22, VK24 and VK8, 
respectively (8–11). The presence of PC-binding antibody 
in the idiotype families T15, M603 and M511 was described 
in studies on hybridoma proteins generated from different 
strains of mice immunized with Streptococcus pneumoniae 
(S. pneumoniae) (R36a) and PC protein (12).
The T15 VH gene family in BALB/c mice includes three 
functional gene segments one of which, the V1 gene segment, 
encodes virtually all VH domains in BALB/c anti-PC antibodies 
(9, 13, 14). In other mouse strains, the T15 VH gene element 
can be matched with its allelic counterpart in BALB/c mice (15). 
The T15 idiotype-positive antibodies dominate the response 
of BALB/c mice to pneumococcal C polysaccharides and are 
important in the protection of mice from experimental pneu-
mococcal infection (16). Thus, the primary antibody response 
after immunization of BALB/c mice with PC-containing anti-
gens, either associated with bacterial polysaccharides or 
coupled to protein carriers, is dominated by the T15 idiotype 
and encoded by the V1 gene. The IgM anti-PC antibodies so 
far reported in the literature have the germline S107 (T15) V1 
heavy-chain V region gene re-arranged to the DFL 16.1 D 
and JH1 gene segments and show the least variations due 
to somatic mutations in their VL and VH sequences (8, 10, 
15, 17). Somatic point mutations of already re-arranged and 
expressed VH1 region gene arose during anti-PC responses 
(18, 19). These V1 gene variants have a conserved site for the 
hapten (PC) and a variable site for the carrier.
However, a single somatically generated base substitution 
in the already re-arranged and expressed heavy-chain V gene 
can lead to a dramatic change in the specificity of this impor-
tant antibody in the mouse (20). One such somatic mutant, U4, 
has lost the ability to bind PC and at the same time acquired 
the ability to bind double-stranded (ds) DNA (21).
Mutations were not detected until the second week after 
immunization and no mutation was found in the IgM antibod-
ies, whereas most of the IgG and IgA antibodies had mutations 
(15, 17). Most of the mutated antibodies had higher affinity 
for antigen than their germline counterparts did (10, 17). The 
binding specificity of antibodies elicited by PC-KLH (keyhole 
limpet hemocyanin, a carrier) in BALB/c mice has shown that 
two distinct populations are expressed in the anti-PC memory 
response (22). Group I antibodies  significantly express the 
T15 idiotype and comprise IgM, IgG3 and IgA antibodies, 
whereas group II antibodies bind p-nitrophenyl phosphocho-
line (NPPC) much better than they bind PC, are T15-idiotype 
negative and comprise most of the IgGl, IgG2a and IgG2b 
antibodies (23). Comparisons of mutated and unmutated T15-
related antibodies showed that mutations caused a decrease 
in binding to S. pneumonia, suggesting that optimal specific-
ity for this molecular form of PC is achieved by the germline-
encoded antibodies (14). Thus, T15 may be unique in the 
failure of mutations to improve antigen binding (24).
In this study, we analysed PC-binding antibodies that were 
reactive predominantly with the PC moiety and that were of 
different idiotypic families, the T15 family after single amino 
acid substitution, the T15 allelic forms, as well as T15 with ran-
dom point mutations in the CDR2 region, with the aim to find 
out whether activities of the PC-binding antibodies toward car-
rier or hapten molecules are hyearchically encoded in their VH 
domain. The analysis was performed using a physicomath-
ematical approach based on the finding that the distribution of 
delocalized electron energies along the protein plays a crucial 
role in determining the protein’s biological activity represented 
as the characteristic frequency component (25–29).
The results presented suggest that binding of the phosphate 
group encoded in the CDR2 region of the PC-reactive antibod-
ies with characteristic frequency at f  =  0.37 Hz is dominant. 
Furthermore, a peptide derived from PC-binding antibodies 
denoted as VH50-73 peptide from the CDR2/FR3 region with 
sequence complementarity (30–32) shows a dominant fre-
quency at f = 0.37 ± 0.05 Hz. However, self-association activity is 
only found in the VH50-73 peptide derived from the T15 proteins 
with f = 0.37 ± 0.05 Hz, which satisfies the criterion of opposite 
phases for proteins that associate with each other (28, 29).
Methods
The H chain V region amino acid sequnces of the T15 hybri-
domas that utilize the VS107 genes and the sequence of its 
somatic mutant used were previously determined by Rudikoff 
et al. (20) and Perlmutter et al. (9), respectively; the sequences 
of the hybridoma proteins of C57BL and CBA/J origin and 
myeloma proteins M603 and M167 are from Clarke et al. (13) 
and Rudokoff and Potter (33), respectively. The T15 variants 
with CDR2 amino acid substitution are from Chen et al. (19).
The analysis of the PC-binding antibody VH sequence was 
performed by applying a physicomathematical model named 
as the informational spectrum method (ISM) and resonant 
recognition model (RRM). The model was described in details 
elsewhere (25–29). A brief description is presented here.
The basic presumption of the model is that the electron-
ion interaction potential of amino acids describes the energy 
states of valence electrons that are important for interaction 
between molecules (25) and that a defined frequency domain 
is represented via a common frequency for proteins with the 
same biological function (26–29). This biological frequency is 
determined in several steps. In the initial step, the sequence 
of protein is converted into a numerical series by assign-
ing to each amino acid the characteristic average energy 
of all valence electrons calculated via pseudopotential (25). 
Numerical series obtained in this way are treated as a signal 
and in the next step are transformed into the frequency domain 
using the Fourier transform. The sampling frequency is fs = 1 
Hz because the distance between molecules is set to d = 1. 
According to the Nyquist theorem, the frequencies of interest in 
power spectra could take values up to 0.5 Hz. In order to deter-
mine the common frequency for the two sequences, the cross-
spectral function was determined according to the formula:
 CSxy f X f Y f f n
f
N
n
Ns( ) ( ) ( )*; ; ,= = =12
2
  (1)
where the X, Y* (asterisk denotes complex conjugate) are 
the Fourier transforms of the first and second sequences and 
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f denotes the frequencies of a certain discrete set of index n 
which runs to N/2, where N represents the number of points 
of Fourier transform. The multiple cross-spectral function of 
several sequences or “consensus spectrum” is calculated by 
the formula:
 CS CS CS CSM M Mf f f f( ) ( ) ( ) ( ),= −12 23 1  
(2)
where the index M denotes the number of sequences. If 
a dominant peak appears in the cross-power spectrum at a 
certain frequency and if it is the signal–noise ratio at this par-
ticular frequency, S/N > 20 (27–29), this frequency can be 
considered relevant for the biological activity. Furthermore, 
from the coefficients X(n) of the corresponding Fourier trans-
formation for a particular sequence of a protein:
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where index m counts the members of the original numeri-
cal series, the amplitude X n( )  and phase spectra j( )n  for 
the characteristic frequency f can be determined (28, 29). 
Based on formula 3, it is possible to determine the phase dif-
ference Dj( )n  between the phase of sequences of protein 
j1( )n  and the phase of its target j2( )n  at a certain frequency 
f or index n:
 ∆ = −j j j( ) ( ) ( )n n n1 2
 
(4)
The experience based on the previous research suggests 
that the difference in phase between a protein and its target 
at a relevant biological frequency should be approximately 
π radians (28). In this study, the cross-spectral function was 
normalized and expressed as a percentage (y-axis) versus 
frequency in Hz (x-axis). Normalized CS was obtained by 
dividing its values with its maximum value and multipling by 
100%.
Results
The present study was carried out to test the hypothesis of 
hierarchically encoded activity in the VH chain sequence 
of PC-binding antibodies. In order to find out whether, 
in the VH sequence of the PC-binding antibodies, hap-
ten or carrier recognition was a dominantly encoded and 
thus represented by a characteristic frequency, a referent 
cross-spectral function was performed for antibodies raised 
against PC when the carrier was a PC-expressing strain 
R36a of S.  pneumoniae. For such analysis, the prototype 
T15 antibody and its allelic form 1613 raised in C57BL mice 
were used. The common frequency component at f = 0.37 
Hz, S/N  =  34.19 is revealed (Fig.  1A). The control cross-
spectral function made with antibodies that lacked specific-
ity for PC (28) reveals a dominant common peak at f = 0.22 
Hz, S/N  =  20.81 (Fig.  1B), meaning that these antibodies 
and PC-binding antibodies do not have a common biologi-
cal activity (Fig. 1A and B).
The PC-specific antibodies T15 and M603 are from two 
different idiotypic families. They do not share specificity for 
the carrier molecule and, in addition, antibody M603 con-
tains amino acid replacements in the CDR2 region of the 
heavy-chain variable region, which indicates that CDR2 is 
also important in recognition of some carrier determinants. 
A direct implication of this finding is that CDR regions may 
accommodate structures larger than PC such as associated 
carrier determinants (34).
In order to see the impact of the mutations in CDR regions 
of M603 with high activity for Proteus morganii on the f = 0.37 
Hz, the cross-spectral function was performed for T15 and 
M603 antibodies. The common dominant frequency compo-
nent is still at f = 0.37 Hz, S/N = 20.01 (Fig. 1C), suggesting 
that this frequency component may characterize interaction 
with the hapten, i.e. PC, rather than with the carrier as PC is in 
the context of different carriers.
These data support the notion that the VH sequence of the 
PC-binding antibodies may encode interaction with hapten 
represented by f = 0.37 Hz as a dominant specificity.
With this thought in mind, we sought to examine the impact 
of mutations impairing antigen binding of the PC-specific T15 
antibodies on the already identified common characteristic fre-
quency f = 0.37 Hz that, we are assuming, delineates binding 
of the PC hapten.
A thorough investigation of the impact of random mutations 
in the H chain CDR2 of the T15 antibody on PC binding has 
been performed (19). It was found that majority of the analysed 
mutant antibodies (e.g., M22) had lost binding for the carbo-
hydrate form of PC that is present in R36a and none of the 
mutated antibodies increased binding activity (19). Mutant anti-
body M296, which has a more than 5-fold decreased binding 
activity to R36a, PC protein (PC histone) and free PC compared 
with wild type and mutant antibody M32, which binds only to PC 
protein and free PC (19) were introduced into the analysis here.
We started the analysis with mutant M22 that lost antigen 
binding for both PC protein and R36a (19). The cross-spec-
tral function involving T15 and its variant M22 is presented in 
Fig. 2A. The analysis shows the new characteristic frequency 
of f = 0.12 Hz, S/N = 8.68. Because M22 lost specificity for 
both hapten and carrier, the data neither confirm nor deny 
that f = 0.37 Hz defines PC binding.
Therefore, T15 and the mutated variant M32 which only binds 
PC protein (19) were introduced into the analysis. The cross-
spectral function showed a characteristic frequency component 
at f = 0.37 Hz with S/N = 8.63 (Fig. 2B). Another T15 mutant M296 
with mutations at different amino acid positions, which binds 
R36a and also binds the PC protein (19), was analysed and the 
cross-spectral function of the T15 and M296 (Fig. 2C) showed a 
similar spectrum to Fig. 2B. A comparison of the cross-spectrum 
shown in Fig. 1A with spectra obtained for mutant T15 proteins 
(Fig. 2A–C) reveals that mutations in the CDR2 have an impact 
on the spectral pattern and consequently on the S/N value and 
thus emphsizes a distinction between wild-type T15 H chain and 
variants with mutation in the CDR2 region.
However, this analysis confirmed that mutations in the 
M32 and M296 are tolerated in the sense that these mutants 
retained both slight domination of the amplitude at f = 0.37 
Hz and an ability to bind PC even when they failed to bind the 
carrier molecule. Thus, at the level of the whole VH domain 
sequence of the PC-binding antibody and even with CDR2 
saturated with point mutations by in vitro random mutagen-
esis (Fig. 2B and C), some mutations are sustainable, as a 
weak ability to bind PC is retained.
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The cross-spectral function was extended to antibodies 
obtained after immunization of different strains of mice 
using different carriers such as bacterial antigens and 
KLH molecules. The obtained cross-spectral function 
involving T15, M167, C57BL 1613, 293, 23169, and CBA/J 
6F9 antibodies is presented in Fig.  2D. The obtained 
data confirmed that f = 0.37 Hz, S/N = 33.6 is a common 
frequency component for all analyzed PC-binding antibodies. 
Furthermore, the pattern of the spectrum is similar to the one 
presented in Fig. 1A.
One may argue that the conclusion about the importance 
of f = 0.37 Hz in the PC binding/recognition might not be cor-
rect as only mutations in the CDR2 region of the VH chain 
were examined and the PC binding site involves other CDR 
regions such as CDR1. Therefore, T15 with a somatic muta-
tion (Glu 35 to Ala) in the VH CDR1 region was introduced 
into the analysis. This single mutation not only resulted in loss 
of binding to PC but also generated new specificity for DNA 
and cardiolipin (20, 21). Residues in the CDR2 form one of 
the three subsites for the contact with PC and interact with 
the dianionic phosphate group, being a crucial portion of the 
phosphate-binding subsite (35).
Unexpectedly, the cross-spectral function (Fig. 3A) of T15 
and T15 with mutation at VH residue 35 (Glu 35 to Ala) showed 
an unchanged common frequency component f  =  0.37 Hz 
but the S/N was < 20 and thus different to the spectral pattern 
presented in Fig. 1A. Because the self-binding or autophilic 
site is still present in the T15 DNA-binding mutant antibody 
(36), this suggests that CDR2 may take part in other impor-
tant activities of PC-binding antibodies such as self-associa-
tion involving the CDR2/FR3 region.
Therefore, the spectrum of the 24-mer peptide (VH50-73) 
derived from either T15 or the C57BL 1613 antibody that is 
allelic to the T15 VH of BALB/c mice (they have identical 
VH50-73), for example from M603 antibody with mutations 
in the CDR2 region, was performed in the next analysis. 
The data presented in Fig.  3B and C showed frequency 
components at f = 0.383 Hz and f = 0.385 Hz, respectively, 
being in the range of the method error (f = 0.37 ± 0.05 Hz) 
with S/N < 20. It should be emphasized that the analysis is 
shown only for T15 mutants exibiting f = 0.37 ± 0.05. The fact 
that the peptides retain the common frequency in the range 
of the method error in spite of the low S/N value may suggest 
that this frequency f  =  0.37 Hz may define binding to the 
phosphate group and the ability to associate with self peptide 
sequences for both heavy chain and VH50-73 peptide. The 
self-binding phenomenon further implies complementarity 
between CDR2 and FR3 regions (31). If this notion is correct, 
Fig. 1. Cross-spectral function of antibody heavy-chain variable region amino acid sequences. (A) Analysis of the PC-binding antibodies: T15 
and 1613 antibody from C57BL mice. (B) Analysis of the non-PC-binding antibodies. (C) Analysis of the PC-binding antibodies belonging to 
different idiotypic families: T15 and M603.
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Fig. 2. Comparison of the cross-spectral function of the heavy-chain variable region amino acid sequences of the T15 antibody, T15 mutants 
with point mutations in the CDR2 region and PC-binding antibodies obtained in conventional immunization. (A) Analysis of the T15 and M22 
mutant. (B) Analysis of the T15 and M32. (C) Analysis of T15 and M296. (D) Analysis of T15, M167, C57BL 1613, 293 and 23169, as well as 
CBA/J 6F9 antibodies.
Fig. 3. Cross-spectral function of the VH regions and VH50-73 peptide sequence derived from different PC-binding antibodies. (A) Analysis of 
the VH region of T15 and T15 with a single mutation in VH CDR1 (Glu 35 to Ala). (B) Analysis of the VH50-73 peptide derived from the sequences 
of the T15 allelic forms, that is T15 and C57BL 1613 antibodies. (C) Analysis of VH50-73 peptide sequence derived from the T15 and M603 
antibodies belonging to different idiotypic families’ antibodies.
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then one may conclude that any PC-binding antibody that 
contains the VH50-73 peptide and that exhibits f = 0.37 ± 
0.05 Hz, including those with natural mutations in the CDR2 
region such as the M603 variant, is a self-binding antibody 
and those that do not bind PC such as M22 are not self-
binding antibodies.
In order to test this presumption, we applied another crite-
rion based on the assumption that proteins share the same 
characteristic frequency with their protein targets but are in 
the opposite phase at this frequency. In this case, the phase 
difference is close to π = 3.14 rad. Thus, this criterion defines 
the complementary sequence of interacting proteins (27, 28). 
The VH50-73 peptide region with previously shown hydro-
patic complementarities, that is VH50-60, is complementary 
to VH 63–74 and forms a self-association region or encode 
self-binding activity (31, 32). The data presented in Table 1 
show that the nearest value to π was found to be 3.5 rad and 
is characteristic only for the VH50-73 regions derived from 
the T15 antibody.
Discussion
The immune response of mice to the PC moiety that is based 
on differential recognition by Id antibodies comprises three 
families (5, 6, 12, 37) of antibodies represented by myeloma 
proteins S107/TEPC-15 (T15), MOPC-167 (M167) and McPC-
603 (M603). The VH1 gene is used to encode their VH regions 
(8, 9, 13–15). These antibodies have extensive homology of 
the heavy chains, similar affinities for the hapten PC, different 
affinities for its structural analogs and binding site diversity for 
different PC-carrier complexes. It seems that the heavy chain 
may well be a prerequisite for all PC-combining activity in mice.
Nuclear magnetic resonance (NMR) data (35) suggest 
a significant degree of conservation of important hapten-
binding site interactions and support the view that the heavy 
chains of these proteins dominate in the interaction with 
bound PC while the various subspecificities of these proteins 
for PC analogs and the carrier itself can be accounted for 
by amino acid changes in the H chain hypervariable regions 
such as CDR2 and CDR3 and in CDR1 (20).
We assessed the phenomenon of a fixed site for PC and 
a variable site for carrier by postulating that binding activity 
for the two antigens should be hierarchically encoded in the 
sequence of the VH chain of the PC-specific antibodies.
The present study was carried out to test this hypothesis 
and the issue was approached by applying a physical and 
mathematical model that interprets the protein’s sequence 
linear information using the signal analysis method of Fourier 
and Wavelet transforms such as the ISM or the RMM method 
(25–29). Previously, the method was used to investigate the 
periodicity of protein structural motifs (27). The dominant peak, 
that is the frequency component in the cross-spectral func-
tion, characterizes biological activity or interactions common 
for all protein sequences analyzed. In accord with this state-
ment, we found that T15 antibody and its allelic form show a 
common dominant frequency (Fig. 1A), which is absent in the 
spectrum of antibodies that are not specific for PC (Fig. 1B).
In nature, the PC antigen exists as the same hapten cou-
pled to widely different carriers such as S, pneumoniae and 
P. morganii. An antibody response to PC in the former context 
was dominated by T15 antibodies, whereas the response to 
P.  morganii was dominated by the M603 family (8, 13–15). 
Thus, between T15 and M603, anti-PC antibody variation 
occurs principally in carrier recognition. The data presented 
here reveal that T15 and M603 antibodies in their cross-
spectral function have the same characteristic frequency 
(Fig. 1C), suggesting that the common frequency at f = 0.37 
Hz defines PC binding activity.
The NMR analysis supported the view that the major contact 
residues for PC are found in the VH chain CDR1 and CDR2 of 
PC-specific antibodies (32 and the references therein).
However, one should keep in mind that the T15 may be 
unique in the failure of mutations to improve antigen binding. 
Therefore, to mimic effects of somatic mutation on PC binding, 
random mutations introduced in vitro by saturation mutagen-
esis of VH CDR2 in murine anti-PC antibody were introduced 
(19). Mutations in at least five different positions in VH CDR2 
of the PC-specific T15 antibody can have a dramatic effect 
on the ability of the antibody to bind PC-containing antigens 
(19). Critical residues at positions Ala-50 and Arg-52 are 
essential for maintaining interaction between the PC and the 
antibody. Mutant M22 (19) that fails to bind PC has a mutation 
at residue 52 and loss of amplitude dominance at f = 0.37 Hz 
(Fig. 2A). However, mutations in VH CDR1 of the T15 antibody 
result in loss of binding to PC but also generated new specifi-
cities for DNA and phosphorylated proteins (20, 21) but the 
characteristic peak at f = 0.37 Hz was not affected (Fig. 3A).
These data forced us to investigate what other activ-
ity might be common for PC-binding antibodies in addition 
to their specificity for the PC and/or phosphate group rep-
resented by the shared frequency component f = 0.37 Hz. 
The answer could be a self-association or autophilic prop-
erty. Furthermore, the self-binding or autophilic site is still 
present on T15 DNA-binding mutant antibody (36), suggest-
ing that CDR2 may take part in another important activity of 
PC-binding antibodies such as self-association. Research on 
self-binding began with the finding of radio-labeled T15 bind-
ing to insolubilized T15, which was interpreted as showing that 
the T15 mimic structure of the PC antigen is important both 
for self-regulation and for conferring the superior protective 
effects of T15 (30, 32). Later on a sequence region in the T15 
VH was identified as having inverse hydropathy and being 
as effective as PC in inhibiting the self-binding complexes 
(31). The part of the CDR2 of the T15 VH region extended 
into the FR3 region was predicted as the primary self-binding 
locus where the CDR2 region (VH50-60) is complementary to 
FR3 sequence (VH63-73) (30–32). The self-binding antibody 
is more potent in protecting mice against pneumoccal infec-
tion than non-self-binding antibodies and conjugation of the 
self-binding or autophilic peptide (T15VH50-73) to antibodies 
Table 1. Correlation between phase differences at the char-
acteristic frequencies with antibody self-binding activity
Self-binding Phase difference
T15 + 3.5
M22 - 1.76
M603 - 9.95
Phase differences are expressed in rad.
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with a different specificity is being considered as a way to 
enhance their therapeutic properties (32).
We argue here that subsite interaction with PC of idiotypi-
cally distinct mouse PC-binding antibodies such as T15 and 
M603 is represented by a characteristic frequency f = 0.37 Hz 
for the VH sequences and f = 0.37 ± 0.05 Hz for the derived 
VH50-73 peptides (which is in the range of the method error). 
However, data concerning complementarity regions of the 
VH50-73 peptide responsible for the self-binding activity 
based on a suggested criterion for the opposite phase (28) 
reveal that self-binding is only an inherent characteristic of 
T15 (Table 1), that is antibodies with the CDR2/FR3 sequence 
ASRNKANDYTTEYSASVKGRFIVS, and this enables the pro-
tective superiority of the T15 antibodies.
Changes of amino acids in the heavy chain CDR2 may 
affect both f = 0.37 Hz (Fig. 2A) and the spectral pattern of 
the mutant antibodies exhibiting decreased activity toward 
the PC moiety (Fig. 2B and C), as well as impairing self-bind-
ing in the case of M603 with naturally occurred mutations in 
CDR2 region (Table 1). These data suggest that according to 
the criterion used in this report, the phosphate-group recog-
nition of PC-binding antibodies is hierarchically encoded in 
the sequence of the heavy-chain variable region. Thus, it is 
tempting to speculate that self-peptides from the self-asso-
ciation or autophilic region of the T15 PC-binding antibody, 
that is antibody raised to polysaccharide epitopes, many of 
which are also self-antigens, in addition to being protective, 
may play an important immunologic role and take part in the 
control of autoimmunity mediated by regulatory T cells (R. 
Metlas and T.  Srdiċ-Rajiċ - Patent application P-2011/0505 
and PC/E/2012/3916, Intellectual Property Office of Serbia).
In summary, the data presented in this report suggest that 
according to the performed analysis, phosphate-group rec-
ognition is represented a the characteristic frequency of the 
PC-binding antibodies and that an ability to associate with self 
peptide sequences is a characteristic of the T15 PC-binding 
antibodies.
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